The AGA recommends endoscopic eradication therapy with radiofrequency ablation, photodynamic therapy or endoscopic mucosal resection, as follows for various patient groups:
• Patients with confirmed high-grade dysplasia (advanced precancerous cells): endoscopic eradication therapy is recommended.
• Patients with confirmed low-grade dysplasia (beginning precancerous cells): endoscopic eradication therapy is a treatment option and should be discussed with patients as such.
• Patients with Barrett’s esophagus without abnormal cells: endoscopic eradication therapy is not recommended.
If eradication therapy is not indicated, is not available or is declined by a patient with Barrett’s esophagus, surveillance by endoscopy should be performed every three months in patients with high-grade dysplasia; every six to 12 months in patients with low-grade dysplasia; and every three to five years in patients with no dysplasia.
Read the AGA news release about endoscopic removal of pre-cancerous cells in patients with high-risk Barrett’s esophagus.
Read other coverage about Barrett’s esophagus:
– Light and Sensors Can Help Detect Esophageal Cancer
– RFA and Endoscopy Treatment May Prevent Barrett’s Esophagus Patients From Surgery
– GI Studies Focus on Barrett’s Esophagus, Endoscopic Ultrasound
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.